Thomas Powles, MBBS, MRCP, MD
In the April 25 issue of The ASCO Post, we reported on a study of atezolizumab -(Tecentriq) and bevacizumab (Avastin) in metastatic kidney cancer, which had been presented at the 2017 Genitourinary Cancers Symposium. Unfortunately, we misattributed that presentation to Prof. Trevor Powles of Barts Cancer Institute and Queen Mary University of London. The study was actually presented by his son, Thomas Powles, MBBS, MRCP, MD, Clinical Professor of Genitourinary Oncology at the same institutions. We apologize to the younger Prof. Powles for the error.
A corrected version of the article appears here: http://www.ascopost.com/issues/april-25-2017/combination-of-atezolizumab-and-bevacizumab-in-pd-l1-positive-patients-with-metastatic-kidney-cancer/. ■